按年龄和性别分析新冠疫苗序贯接种与SARS-CoV-2感染后心肌炎风险
该研究基于英格兰2020年12月至2021年12月13岁及以上人群的自控病例系列,评估新冠疫苗接种与心肌炎的关联。整体上感染后心肌炎风险高于接种后,但年轻男性接种mRNA-1273第二剂后风险较高。
要点
- 新冠感染后心肌炎风险高于疫苗接种后。
- 年轻男性接种mRNA-1273第二剂后心肌炎风险升高。
- BNT162b2加强剂后心肌炎风险仍较轻微。
核心结论
- 整体上SARS-CoV-2感染后心肌炎风险大于新冠疫苗接种后,包括BNT162b2 mRNA疫苗加强剂在内的序贯接种后风险仍较轻微。
- 年轻男性接种后心肌炎风险较高,尤其是mRNA-1273第二剂后。
研究设计与样本
- 英格兰2020年12月1日至2021年12月15日13岁及以上接种新冠疫苗人群的自控病例系列研究,按年龄和性别分层。
主要发现
- 2861人(0.007%)发生心肌炎,其中617例事件发生在接种后1-28天。
- ChAdOx1第一剂后1-28天心肌炎风险增加(IRR 1.33,95%CI 1.09-1.62)。
- BNT162b2第一、第二和加强剂后1-28天心肌炎风险增加(IRR分别为1.52 [95%CI 1.24-1.85]、1.57 [95%CI 1.28-1.92]、1.72 [95%CI 1.33-2.22])。
- mRNA-1273第二剂后1-28天心肌炎风险更高(IRR 11.76,95%CI 7.25-19.08),加强剂后仍持续(IRR 2.64,95%CI 1.25-5.58)。
- 所有疫苗在40岁以下男性中关联更强。
关键数值与推荐
- 接种后心肌炎风险低于SARS-CoV-2检测阳性后(接种前阳性IRR 11.14 [95%CI 8.64-14.36],接种后阳性IRR 5.97 [95%CI 4.54-7.87])。
- 40岁以下男性每百万人超额心肌炎事件:mRNA-1273第二剂后97(95%CI 91-99),SARS-CoV-2阳性后16(95%CI 12-18)。
- 40岁以下女性每百万人超额事件:mRNA-1273第二剂后7(95%CI 1-9),SARS-CoV-2阳性后8(95%CI 6-8)。
临床怎么用
- 临床评估心肌炎风险时应考虑年龄和性别,年轻男性接种mRNA-1273第二剂后风险较高。
- 整体上新冠感染后心肌炎风险高于疫苗接种后,疫苗接种的获益仍支持推荐。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Myocarditis is more common after severe acute respiratory syndrome coronavirus 2 infection than after COVID-19 vaccination, but the risks in younger people and after sequential vaccine doses are less certain. METHODS: A self-controlled case series study of people ages 13 years or older vaccinated for COVID-19 in England between December 1, 2020, and December 15, 2021, evaluated the association between vaccination and myocarditis, stratified by age and sex. The incidence rate ratio and excess number of hospital admissions or deaths from myocarditis per million people were estimated for the 1 to 28 days after sequential doses of adenovirus (ChAdOx1) or mRNA-based (BNT162b2, mRNA-1273) vaccines, or after a positive SARS-CoV-2 test. RESULTS: In 42 842 345 people receiving at least 1 dose of vaccine, 21 242 629 received 3 doses, and 5 934 153 had SARS-CoV-2 infection before or after vaccination. Myocarditis occurred in 2861 (0.007%) people, with 617 events 1 to 28 days after vaccination. Risk of myocarditis was increased in the 1 to 28 days after a first dose of ChAdOx1 (incidence rate ratio, 1.33 [95% CI, 1.09-1.62]) and a first, second, and booster dose of BNT162b2 (1.52 [95% CI, 1.24-1.85]; 1.57 [95% CI, 1.28-1.92], and 1.72 [95% CI, 1.33-2.22], respectively) but was lower than the risks after a positive SARS-CoV-2 test before or after vaccination (11.14 [95% CI, 8.64-14.36] and 5.97 [95% CI, 4.54-7.87], respectively). The risk of myocarditis was higher 1 to 28 days after a second dose of mRNA-1273 (11.76 [95% CI, 7.25-19.08]) and persisted after a booster dose (2.64 [95% CI, 1.25-5.58]). Associations were stronger in men younger than 40 years for all vaccines. In men younger than 40 years old, the number of excess myocarditis events per million people was higher after a second dose of mRNA-1273 than after a positive SARS-CoV-2 test (97 [95% CI, 91-99] versus 16 [95% CI, 12-18]). In women younger than 40 years, the number of excess events per million was similar after a second dose of mRNA-1273 and a positive test (7 [95% CI, 1-9] versus 8 [95% CI, 6-8]). CONCLUSIONS: Overall, the risk of myocarditis is greater after SARS-CoV-2 infection than after COVID-19 vaccination and remains modest after sequential doses including a booster dose of BNT162b2 mRNA vaccine. However, the risk of myocarditis after vaccination is higher in younger men, particularly after a second dose of the mRNA-1273 vaccine.
引用
- Patone M, Mei XW, Handunnetthi L, et al. Risk of Myocarditis After Sequential Doses of COVID-19 Vaccine and SARS-CoV-2 Infection by Age and Sex. Circulation. 2022. PMID: 35993236. doi:10.1161/CIRCULATIONAHA.122.059970
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。